Arbutus Biopharma Corporation (NASDAQ:ABUS) announced today that the U.S. Food and Drug Administration has granted Fast Track designation to imdusiran for treating chronic hepatitis B.

imdusiran (AB-729) - Arbutus

Apr 15, 2026